After a brutal stretch that battered its stock and its reputation, UnitedHealth Group (UNH +1.40%) is leaning hard into artificial intelligence to steady the ship. The company is investing about $1.5 billion in AI across its operations this year, and management told investors on its first-quarter 2026 earnings call that it expects a conservative 2-to-1 return on that spending over the next few years, with many tools paying for themselves within 12 to 18 months. For anyone weighing the bull case, the question is whether those numbers are real or aspirational.
Where the money is going
The spending is split deliberately. Roughly one-third is flowing into software products and platforms to push its Optum Insight unit toward an "AI-first" model, while the other two-thirds is spread across everyday processes like claims and prior authorization. The company says it has identified more than 1,000 potential AI use cases.
Image source: Getty Images.
What makes the story more than a slide deck is that some results are already showing up. At Optum Rx, an AI prior-authorization tool has cut prescription approval times from more than eight hours to under 30 seconds, while denials tied to missing information fell 68% and appeals dropped 88%. Call-center volume is down 25% as members shift to AI-enabled self-service, and its OptumReal claims platform has handled roughly 500 million claims so far this year, on track for 2.5 billion transactions by year-end.
What it means for the bull case
Put together, the bull case is straightforward: Optum expects AI-driven efficiency to deliver close to $1 billion in cost reductions this year, which flows almost directly to profit. For a company trying to rebuild margins and investor trust, that's a meaningful tailwind, and the pivot toward selling AI software to other healthcare players could open a higher-quality revenue stream over time. If even the "conservative" 2-to-1 return materializes across a $1.5 billion base, the payoff compounds year after year.
The risks worth naming
I'd temper the enthusiasm, though. That 2-to-1 figure is a projection, not a result, and grand ROI targets have a way of slipping. More importantly, using AI to speed up claims and prior-authorization decisions is exactly the kind of activity now drawing lawsuits and regulatory scrutiny across the insurance industry, where critics worry algorithms are being used to deny care. UnitedHealth is deploying these tools while still working through the broader troubles that hit it hard, so execution is far from guaranteed.
NYSE: UNH
Key Data Points
UnitedHealth's AI push gives the bull case something concrete to point to: a defined investment, early operational wins, and a credible path to real savings. That strengthens the turnaround argument. But treat the 2-to-1 return as a goal to verify quarter by quarter, not a promise, and keep an eye on the legal and political risks that come with automating decisions about people's healthcare.
